(Q45007089)

English

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

fluticasone propionate

1 reference

based on heuristic

inferred from title

author name string

Richard D O'Connor

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Harold Nelson

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rohit Borker

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Amanda Emmett

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Priti Jhingran

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Kathleen Rickard

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Paul Dorinsky

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

815-825

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Assessing the appropriateness of combining economic data from multinational clinical trials

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422120-00004

21 January 2018

Reimbursements. Inching closer to actual charges

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost of asthma in the emergency department and hospital

1 reference

https://pubmed.ncbi.nlm.nih.gov/15294013

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200422120-00004

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Dimensions Publication ID

0 references

release_s6dgs7vwefbvzmfgb7hr4p5qea

1 reference

https://api.fatcat.wiki/v0/release/s6dgs7vwefbvzmfgb7hr4p5qea

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45007089&oldid=2207042383"